Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ: CNSP )

0.1400 +0.0322 (+29.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,283,273
Open 0.1564
Bid (Size) 0.1282 (2)
Ask (Size) 0.1326 (65)
Prev. Close 0.1078
Today's Range 0.1330 - 0.1900
52wk Range 0.0820 - 23.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Check out the stocks that are attracting the most attention and driving market activity.
Let's dive into the action on the US markets on Friday. Here are the most active stocks that are driving the market today. 
Via Chartmill
What's going on in today's session
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill

Performance

YTD
+19.76%
+19.76%
1 Month
+28.68%
+28.68%
3 Month
+16.67%
+16.67%
6 Month
-2.98%
-2.98%
1 Year
-99.02%
-99.02%

More News

Read More
Friday's session: gap up and gap down stocks
Via Chartmill
Top movers in Friday's pre-market session
Via Chartmill
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
Via ACCESS Newswire
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference
Via Investor Brand Network
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
New Graphene Chip Could Revolutionize Brain Cancer Treatment
Via Investor Brand Network
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Via ACCESSWIRE
Study Reveals Insights into How Needed Treatments Can Bypass the Blood-Brain Barrier
Via Investor Brand Network
Chinese Research Team Suggests Common Drug for Blood Pressure Could Treat Invasive Brain Tumor
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Research Shows Brain Tumors Grow by Hijacking Circadian Clocks
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11
Via Investor Brand Network
AI Model Promises New Way to Detect Brain Malignancies
Via Investor Brand Network
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma Treatment
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Via ACCESSWIRE
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting
Via Investor Brand Network
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.